通过调节AXL介导的MAPK/NF-κB信号通路,C1632可以防止LPS引起的急性肺损伤
Yanan Mei1, Yihang Wu1, Yihui Zhai2
1Respiratory Medicine Department, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325027, China; School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang 325035, China.
International immunopharmacology
|March 25, 2025
概括
通过向AXL受体和MAPK/NF-κB通路,C1632有效地治疗急性肺损伤 (ALI) 和急性呼吸困扰综合征 (ARDS). 这种新型治疗剂可以减少肺炎和损伤,而不会产生显著的毒性.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 肺部医学 肺部医学
背景情况:
- 急性肺损伤 (ALI) 和急性呼吸困难综合征 (ARDS) 是具有高死亡率的危急疾病.
- TAM受体AXL与先天性免疫和炎症反应有关.
研究的目的:
- 为了研究C1632的治疗疗效和机制,在一个小鼠模型的脂聚糖化物 (LPS) 诱导的ALI/ARDS.
- 评估C1632作为ALI/ARDS新疗法的潜力.
主要方法:
- 在LPS挑战之前,小鼠先用C1632进行预治疗.
- 评估了炎症标志物 (IL-6,TNF-α),粘附分子 (VCAM-1,ICAM-1),炎症细胞透和肺部组织病理学.
- 研究了C1632对AXL表达和MAPK/NF-κB信号通路激活的影响.
- 评估的C1632细胞毒性和器官毒性在体外和体内.
主要成果:
- C1632预处理显著抑制LPS诱导的炎症因子产生和血管粘附分子表达.
- C1632减少了炎症细胞的透,并减轻了肺部的病原体损伤.
- C1632抑制了AXL转录和表达,抑制了LPS诱导的MAPK/NF-κB通路激活.
- C1632在小鼠中没有显著的细胞毒性或损害肝脏和功能.
结论:
- 在ALI/ARDS中,AXL是通过MAPK/NF-κB信号通路调解的抗炎治疗的可行的治疗标.
- C1632表明作为ALI/ARDS的安全有效治疗剂具有前途.
相关概念视频
NF-κB-dependent Signaling Pathway
7.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.2K
MAPK Signaling Cascades
5.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.0K


